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Marion S. Greene 
THE RISKS AND CONSEQUENCES OF OPIOID MISUSE 
 
Opioid misuse and addiction has been widely identified as a public health 
problem, contributing substantially to the nation’s morbidity and mortality. Over the 
past two decades, misuse of prescription opioids pain relievers has substantially 
increased; heroin use has resurged; and, more recently, abuse of high-potency synthetic 
opioids such as fentanyl have fueled the epidemic. Nearly 12 million Americans (or 
4.4%) aged 12 and older misused some type of opioid (prescribed or illegal) in the past 
year. Furthermore, the percentage of substance use treatment admissions attributable 
to opioids nearly doubled in the U.S., from 20.8% in 2000 to 40.5% in 2015. 
The purpose of this dissertation research was to investigate associations 
between prescription pain reliever use and subsequent negative health outcomes, 
including opioid misuse or addiction, and neonatal abstinence syndrome. This research 
focused on three specific aims: 
Specific Aim #1: Examine heroin use among Indiana’s substance use treatment 
population to measure the extent, trends, and patterns of use, as well as to assess the 
relationship between prescription opioids and subsequent heroin use; 
Specific Aim #2: Analyze 2014 INSPECT (Indiana’s prescription drug monitoring 
program) data to identify factors that increase patients’ likelihood to engage in opioid-
related risk behaviors; and 
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Specific Aim #3: Review U.S. trends in neonatal abstinence syndrome (NAS) 
incidence from 2008-2014, measure regional variability, and identify personal and 
environmental risk factors associated with NAS. 
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CHAPTER 1  
1.1. Introduction  
Opioid misuse and addiction has been widely identified as a public health 
problem, contributing substantially to the nation’s morbidity and mortality.1-3 Over the 
past two decades, misuse of prescription opioids (pain relievers) has substantially 
increased; heroin use has resurged; and, more recently, abuse of high-potency synthetic 
opioids such as fentanyl have fueled the epidemic.4 Nearly 12 million Americans (or 
4.4%) aged 12 and older misused some type of opioid (prescribed or illegal) in the past 
year.5 Furthermore, the percentage of substance use treatment admissions attributable 
to opioids nearly doubled in the U.S., from 20.8% in 2000 to 40.5% in 2015.6  
The consequences of opioid misuse are substantial. Drug overdoses, which are 
the leading cause of injury-related death in the nation,7 are occurring at an increasing 
rate8 and have tripled in the past 15 years.3 Overdoses attributable to opioids resulted 
in more than 750,000 emergency department (ED) visits9 and over 33,000 deaths in 
2015.4,10 From 2005 to 2014, rates of opioid-related ED visits nearly doubled and rates 
of opioid-related inpatient stays increased by more than 64 percent.11 Age-adjusted 
mortality rates per 100,000 have increased to 5.9 for those involving prescription 
opioids and 3.4 for those involving heroin in 2014.12  
Furthermore, neonatal abstinence syndrome (NAS), a condition caused by the 
abrupt discontinuation of chronic exposure to drugs and other substances used by the 
mother during pregnancy,13 has been on the rise. According to recent studies, NAS 
incidence rates increased nearly five-fold since 2000 to 5.8 per 1,000 hospital births in 
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2012.14,15 To illustrate the magnitude of this problem, it has been stated that 
“approximately one infant [is] born per hour in the United States with signs of drug 
withdrawal”.14  
1.2.  Conceptual Framework  
Many factors have contributed to the opioid epidemic (Figure 1.1). Over the past 
two decades, the United States has seen a substantial increase in the sale of 
prescription pharmaceuticals,16 especially opioids.17 Sales of prescription pain relievers 
nearly doubled from 105 million in 1998 to 207 million in 2013.18 Rising sales and wide 
availability of these drugs have been linked to the increase in opioid misuse, addiction, 
and overdose deaths.19-22 The increase in sales has been attributed, at least in part, to 
two events that started in the 1990s – the push to adopt pain as the fifth vital sign and, 
subsequently, the aggressive marketing of opioids by the pharmaceutical industry, 
especially Purdue Pharma which had just released OxyContin®.4   
In response to increasing accounts of “undertreatment of pain” and 
“pseudoaddiction,”23-25 the American Pain Society began promoting “pain as the 5th 
vital sign” in the mid-1990s, in an effort to increase awareness among healthcare 
professionals.26 The U.S. Department of Veterans Affairs (VA) and the Joint Commission 
on Accreditation of Healthcare Organizations (JCAHO) both endorsed the campaign and 
changed their pain management standards to focus on patients’ rights to assessment 
and treatment of pain.26-28 Encouraged by the growing movement, Purdue Pharma 
promoted a more liberal use of opioids, especially among primary care physicians, and 
aggressively marketed OxyContin for the non-cancer pain market, leading to a nearly 
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ten-fold increase in the number of OxyContin prescriptions for non-cancer pain, from 
670,000 in 1997 to over 6 million in 2002.4,29     
More recently, in an effort to control the opioid epidemic, federal and state 
governments started implementing a variety of policies and programs to curb 
inappropriate prescribing.30 These strategies included education on appropriate use as 
well as the risks and benefits of opioids, promotion of opioid prescribing guidelines for 
healthcare professionals, development of prescription pain relievers using abuse-
deterrent technologies, and implementation of statewide prescription drug monitoring 
programs (PDMPs).30-32 
Following these efforts to decrease prescription opioid misuse, the country has 
also witnessed an increase in heroin use and overdose deaths.30,33 While the literature 
on the progression from prescription opioids to heroin is still sparse, some studies 
suggest a connection since these drugs are pharmacologically similar34,35 and the rate of 
heroin use is higher among individuals who first misused prescription opioids.33,36-38     
     
4 
Figure 1.1. Conceptual Framework 
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1.3. Specific Aims 
The purpose of this dissertation was to investigate associations between 
prescription pain reliever use and subsequent negative health outcomes, including 
opioid misuse or addiction and neonatal abstinence syndrome. This research focused on 
three specific aims: 
Specific Aim #1: Examine heroin use among Indiana’s substance use treatment 
population to measure the extent, trends, and patterns of use, and to assess the 
relationship between prescription opioids and subsequent heroin use; 
Specific Aim #2: Analyze 2014 INSPECT (Indiana Scheduled Prescriptions 
Electronic Collection and Tracking; i.e., the state’s prescription drug monitoring 
program) data to identify factors that increase patients’ likelihood to engage in opioid-
related risk behaviors; and 
Specific Aim #3: Review U.S. trends in neonatal abstinence syndrome (NAS) 
incidence from 2008-2014; measure regional variability; and identify personal and 
environmental risk factors associated with NAS. 
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CHAPTER 2 The Relationship between Heroin and Prescription Opioid Use in Indiana’s 
Substance Use Treatment Population: A Cross-Sectional Analysis 
2.1.  Specific Aim #1 
Chapter 2 addresses the Specific Aim #1, as outlined in the abstract.  The 
purpose is to examine heroin use among Indiana’s substance use treatment population 
to measure the extent, trends, and patterns of use, as well as to assess the relationship 
between prescription opioids and subsequent heroin use.  
2.2.  Introduction  
Heroin is a highly addictive opioid39 and, although it represents less than five 
percent of all illicit drug use, its impact is said to exceed that of more widely used 
substances.40 The majority of individuals with a heroin use disorder develop 
dependence (84%).41 Many negative consequences are associated with the use of this 
drug, some of which are attributable to its primary route of administration, injection. 
These outcomes include: addiction;42,43 infections of HIV, hepatitis B and C, and 
tuberculosis;44-47 pregnancy complications and neonatal abstinence syndrome;48-50 and 
drug overdoses.7,51 Drug overdoses are the leading cause of injury-related death in the 
nation7 and the U.S. mortality rate for overdoses involving heroin nearly tripled from 1.0 
per 100,000 in 2010 to 2.7 per 100,000 in 2013. Furthermore, the economic burden of 
heroin addiction in the United States was an estimated $21.9 billion in 199640 and the 
costs specifically associated with heroin-related overdoses were estimated at $4.6 
billion in 2009.52  
Although heroin use within the general population is fairly low, there has been a 
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significant increase from 2005 through 2011 in past-year initiation, use, and 
dependence.53 The reasons for the rise are still uncertain, but a connection to the 
prescription opioid epidemic has been proposed. There is biological plausibility for this 
argument, since both drugs belong to the opioid category and, therefore, share similar 
chemical structures and comparable pharmacological effects.53,54 Concerns have been 
voiced among treatment providers, researchers, and policymakers that nonmedical use 
of prescription opioids may progress to heroin use, so understanding the relationship 
between the two is crucial for developing clinical guidelines and public health 
interventions.43,51,53,55 Greater availability of prescription opioids has been linked to 
higher substance misuse rates;21 consumption, treatment admissions, and overdose 
deaths attributable to prescription pain relievers have increased substantially over the 
past 15 years, paralleling the increase in opioid sales.43,56 While the literature on 
progression from prescription opioids to heroin is still sparse, Muhuri, et al.53 found a 
strong association between prior nonmedical pain reliever use and subsequent heroin 
initiation in U.S. residents ages 12 to 49. They estimated that the rate of heroin initiation 
among individuals who engaged in prior nonmedical use of prescription opioids was 
approximately 19 times greater than those who did not.53  
It has been suggested that heroin users are not a homogeneous group and that 
those who progressed from prescription opioids to heroin are socio-demographically 
different from other heroin users.55 Patterns and trends of use vary within the United 
States and the Midwest has been particularly impacted by heroin.7 While there are no 
state-level prevalence estimates for heroin use available for Indiana, existing data 
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indicate that this drug has become a significant public health problem in the state. In 
Indiana, the percentage of substance use treatment admissions for heroin quadrupled 
from 2.6 percent in 2001 to 11.1 percent in 201257 and the number of overdose deaths 
listing heroin as a contributing causei increased from 3 in 2000 to 152 in 2013.58,59 There 
has also been a marked increase in heroin trafficking as evidenced by the number of 
heroin seizures across Indiana, which increased an estimated 300 percent between 2011 
and 2013. Most of the heroin seizures occurred around Interstate 65, which connects 
Chicago, a major hub for heroin, to Indianapolis.60   
The purpose of this study was to examine heroin use among Indiana’s substance 
use treatment population to gain a better understanding of the extent, trend, and 
pattern of use within the state, as well as to assess the relationship between 
prescription opioid misuse and subsequent heroin use. While Muhuri et al.53 already 
established this link within the general U.S. population ages 12 to 49, the question 
remains if the same pattern holds true for Indiana and with a population presumably 
more severely impacted, since my study sample included low-income individuals who 
received substance use treatment services. 
2.3.  Methods 
2.3.1.  Study Design, Population, and Data Source 
This study used a retrospective, cross-sectional examination of administrative 
records from the Treatment Episode Data Set - Admissions (TEDS-A), covering a five-
                                                           
i Underlying cause of death ICD-10 codes: X40-X44, X60-X64, X85 or Y10-Y14 with contributing cause 
of T40.1.  
 9 
 
 
year study period from January 1, 2008, through December 31, 2012. TEDS-A is a 
national census data system of annual admissions to substance use treatment facilities. 
State law requires publicly funded drug treatment programs to routinely collect 
information on the number and characteristics of persons admitted to their programs 
and report these data to a state agency.57  In Indiana, these data are reported to the 
Indiana Family and Social Services Administration’s Division of Mental Health and 
Addiction. Treatment settings include inpatient/outpatient, residential, short- and long-
term programs, and a small percentage of programs that provide medication-assisted 
opioid therapy. The collected information is then submitted in standard format to the 
Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for 
Behavioral Health Statistics and Quality. TEDS-A records represent admissions rather 
than individuals, thus individuals may be admitted to treatment more than once in a 
given year.57 All Indiana treatment admissions from 2008 through 2012 were included in 
the analyses, resulting in 117,230 observations. This study was determined to be 
exempt from IRB review by the Indiana University Institutional Review Board.  
2.3.2.  Analyses  
Four types of analyses were conducted for this study with treatment admission 
as the unit of analysis: (1) Descriptive statistics were employed to summarize the 
characteristics of those represented among Indiana’s treatment admissions; (2) Simple 
logistic regression analyses were used to review the five-year trend of heroin and 
prescription opioid misuse. For this analysis, heroin misuse (binary variable) and 
prescription opioid misuse (binary variable) were the dependent variables, separately, 
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and year of treatment admission was the independent variable. The observed 
percentages of misuse by year were plotted for each drug; (3) To test the relationship 
between heroin and prescription opioid misuse, a multiple logistic regression analysis 
was conducted, adjusting for client characteristics and time. Heroin misuse was the 
outcome of interest or dependent variable and prescription opioid misuse was the 
independent variable; the covariates included gender, age group, race, ethnicity, and 
year of treatment admission; (4) Age of first use was compared among those who 
reported using both heroin and prescription opioids to determine which of these 
substances tended to be initiated first.  
Whenever appropriate, odds ratios and 95% Wald confidence intervals (95% CI) 
were computed. All analyses were conducted using Statistical Analysis Software SAS® 
version 9.4. Results with p-levels less than 0.05 were deemed statistically significant.  
2.4.  Results 
2.4.1.  Description of Study Population  
The number of substance use treatment admissions in Indiana rose from 19,111 
in 2008 to 25,026 in 2012 as shown in Table 2.1. While the majority of admissions were 
for males, the percentage of women among the treatment admissions increased 
consistently from 32.5% in 2008 to 37.2% in 2012. Throughout the five-year period, 
most of Indiana’s treatment admissions were for whites, non-Hispanics, and individuals 
aged 21 through 49 years.  
Alcohol and marijuana were the most widely used substances among those 
admitted for treatment; however, treatment admissions for alcohol and marijuana 
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misuse decreased proportional during these five years from 71.0% to 59.4% and from 
55.1% to 47.2%, respectively. Admissions for cocaine use dropped from 21.4% in 2008 
to 15.9% in 2012. At the same time, admissions for prescription opioids rose from 13.7% 
to 22.0%, replacing cocaine as the third most frequently reported drug of misuse. 
Admissions for heroin use nearly tripled from 4.1% to 11.1%. Furthermore, 
polysubstance use was common within Indiana’s treatment admissions with nearly two-
thirds of clients reporting the use of two or more substances. 
Client characteristics were somewhat differently distributed among heroin and 
prescription opioid users compared to the overall treatment population as shown in 
Table 2.2. Combined data from 2008 through 2012 show that among admissions for 
heroin and prescription opioid use, the percentage of women (41.5% and 48.5% 
respectively) was considerably higher than among the overall treatment population 
(35.6%); also, heroin or prescription opioid users were slightly younger. The majority of 
all clients admitted for treatment were white (79.8%); however, the percentage of 
whites was notably higher among heroin (87.4%) and prescription opioid users (93.4%). 
Among heroin users, marijuana (28.3%), cocaine (25.2%), and prescription opioids 
(22.9%) were, in addition to heroin, the most widely used substances. Those admitted 
for prescription opioid use reported also using marijuana (40.8%), alcohol (34.9%), and 
benzodiazepines (18.0%), in addition to prescription opioids. Polysubstance use was 
more prevalent among both heroin (79.3%) and prescription opioid misusers (82.6%) 
compared to the overall treatment population (60.7%). Injection drug use (IDU), which is 
often the preferred route of heroin administration, was reported in 69.0% of admissions 
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for heroin use, compared to 17.7% of admissions for prescription opioid use and 8.6% of 
the overall treatment population.  
2.4.2.  Heroin and Prescription Opioid Trends from 2008 through 2012 
Findings from the simple logistic regression analyses shown in Figure 2.1 
indicated there was a significant increasing trend in heroin use in Indiana’s treatment 
population throughout the five-year period, from 4.1% (n=777) in 2008 to 11.1% 
(n=2,767) in 2012.  Similarly, prescription opioid use among Indiana’s treatment 
population rose significantly from 13.7% (n=2,615) in 2008 to 22.0% (n=5,498) in 2012 
(all p<0.0001). 
2.4.3.  Association of Heroin and Prescription Opioid Use 
In addition, a multiple logistic regression analysis was conducted to assess if the 
risk (odds) of heroin use was greater among admissions of clients who also reported 
using prescription opioids. The analysis adjusted for client characteristics that are known 
to affect drug use patterns in general; i.e., gender, race, ethnicity, and age, as well as 
year of treatment admission. The adjusted odds ratios are shown in Table 2.3. 
The overall model was significant in predicting heroin use (p<0.0001), showing 
an 18 percent increase in the odds of using heroin among admissions where clients also 
reported use of prescription opioids (OR=1.18; 95% CL: 1.11-1.25), adjusting for client 
characteristics and time. Furthermore, heroin use was linked to being female (OR=1.20; 
95% CL: 1.15-1.26), white (OR=1.53; 95% CL: 1.34-1.75), Hispanic (OR=1.18; 95% CL: 
1.06-1.31), and of younger age, especially aged 21 to 34 (OR=1.93; 95% CL: 1.76-2.12). 
Year of treatment admission was also associated with heroin use. Between 2008 and 
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2012, each subsequent year increased the odds of reported heroin use by 31 percent 
(OR=1.31; 95% CL: 1.28-1.33).  
2.4.4.  Opioid Initiation among Dual Users 
Overall, 1.8% of the treatment population were dual users; i.e., they reported 
using both heroin and prescription opioids. One-tenth (10.1%) of prescription opioid 
users and more than one-fifth (22.9%) of heroin users reported using both drugs. 
Among admissions with dual use, 51.2% (n=721) initiated prescription opioids before 
heroin, while only 8.2% (n=115) used heroin prior to prescription opioids; in 40.7% 
(n=573), no differences could be ascertained since initiation of both drugs occurred 
within the same age category.  
Distribution of initiation patterns differed by drug use category as shown in 
Table 2.4. Among admissions with dual use, nearly one-third (32.8%) initiated 
prescription opioids prior to the age of 18, while only 16.7% began using heroin at this 
age. Most opioid initiation in that group occurred between the ages of 18 and 34, with 
77.0% of dual users initiating heroin and 58.6% initiating prescription opioids at that 
time. The percentage of clients who used heroin prior to the age of 18 for the first time 
was higher among those who did not engage in dual use (25.6%) compared to those 
who engaged in dual use (16.7%). 
2.5.  Discussion 
Overall opioid use, i.e., prescription and heroin, has increased steadily for at 
least the past five years in Indiana’s substance use treatment population and findings 
from this study indicated a clear relationship between the use of heroin and prescription 
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opioids. Thus far, only a limited number of studies have formally tested the transition 
from prescription opioids to heroin51,53 and some small-scale studies have shown that 
for a large proportion of heroin users, prescription pain relievers served as a gateway to 
heroin,38,55 particularly among heavy users.61 Primary reasons frequently cited for 
switching included lower costs, easier access and increased availability, as well as 
greater effectiveness of heroin in producing a “high,” combined with the reformulation 
of OxyContin® in 2010, which made it more difficult to abuse.43,51,62,63 
While the existing data set used for this study did not allow to formally test the 
question of transitioning, the results suggested this occurs frequently, since the majority 
of clients in treatment who used both drugs reported using prescription opioids prior to 
heroin initiation. Nearly one-third of dual users started using prescription opioids during 
adolescence, while a considerably lower percentage reported initiating heroin use 
during that period.  
The literature, as well as the present study, support the belief that the increase 
in heroin use has been a corollary of the prescription drug epidemic.43,51,53,55 Some 
concerns have been voiced that the rise in heroin consumption was an unintended 
consequence of national and state efforts to prevent misuse and diversion of 
prescription opioids. While the increase in heroin use occurred largely after the 
implementation of statewide strategies and policies to reduce prescription opioid 
misuse, it is yet to be determined if this relationship was causal. Prevention efforts were 
successful in reducing use and availability of prescription opioids, which may have 
encouraged some patients to switch to heroin.  However, these public health 
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approaches aimed at mitigating prescription-drug misuse were a direct response to the 
rising numbers of pain reliever misuse and deaths, which preceded the increase in 
heroin use. It has been suggested that “inappropriate prescribing of opioid 
medications,”64 sometimes out of fear to undertreat pain,24 has unintentionally 
contributed to the escalation in opioid dependence and its consequences.  
Findings of this study have significant public health implications related to IDU.  
Heroin users are at an increased risk for HIV and hepatitis B and C transmissions due to 
the large percentage of users who inject the drug intravenously.51 IDU has been linked 
to the spread of these diseases primarily by the mechanism of sharing contaminated 
needles and syringes. A large percentage of injection drug users, especially those with a 
history of arrests and lower socio-economic status, share their injection paraphernalia, 
even though they have knowledge of the associated risks of infection.65,66 This study 
found that in 69% of the admissions for heroin use, clients reported injection as their 
primary route of administration, a percentage nearly four times higher than for 
prescription opioid use admissions and eight times higher than for the overall treatment 
population. The high percentage of drug injection practices among Indiana’s substance 
use treatment population puts them at significant risk for infection with HIV as well as 
hepatitis B and C, which also spreads the risk to family and friends with whom they 
share injection equipment or have sexual relationships. Providing broad access to 
evidence-based programs, particularly medication-assisted therapies, has been shown 
to be cost-effective in treating opioid addiction and reducing negative consequences, 
including the transmission of HIV.67-69 However, the extension of such services would 
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require an expansion of the state’s addiction workforce to narrow the gap between 
demand and supply.70,71   
2.5.1.  Strengths and Weaknesses of the Study 
A strength of the study was its large sample size (n=117,230) and reliability of 
the data. TEDS-A data have been routinely collected by state agencies under federal 
guidance of SAMHSA since 1989.  
Several limitations of the data have been identified. Records represent 
admissions rather than individuals; thus, individuals may be admitted to treatment 
more than once in a given year. Only publicly funded substance use treatment providers 
are required to collect and submit client information.  Thus, the number and 
characteristics of clients receiving these services depends, to some extent, on external 
factors, including funding levels and selective targeting of high-risk groups. Additionally, 
Indiana only collects data on clients who are at or below the 200% federal poverty level. 
Hence, findings presented in this report may not be representative of the state’s entire 
treatment population. Though the dataset does not represent the total demand for 
treatment in the state, it does comprise a significant proportion of all admissions to 
substance use treatment. 
Another limitation of the dataset was the absence of information on clients’ 
mental health or smoking status since both have been identified as risk factors for 
addiction.72,73   
2.5.2.  Suggestions for Future Research  
Demographic characteristics of heroin users in treatment have shifted over the 
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past 50 years, away from inner-city minority groups. Now the majority of users are 
white and nearly evenly distributed between males and females.74 It has been suggested 
that individuals who progressed from prescription opioids to heroin are socio-
demographically different from heroin users who did not follow this trajectory.55 Even 
findings from this study suggest that heroin users who do not engage in prescription 
opioid misuse may start using heroin at an earlier age than those who engage in dual 
use.  Follow-up studies on client characteristics comparing these two groups could assist 
clinicians and the treatment community in developing evidence-based intervention 
programs for specific high-risk populations. 
2.5.3.  Conclusion 
The misuse of prescribed and illicit opioids has increased dramatically over the 
past few years in Indiana. While this study found a significant association between 
prescription drug misuse and heroin use, it is likely that other factors play a major role 
as well. Public health strategies to curb the opioid epidemic need to include policies and 
laws to educate healthcare providers and regulate prescribing practices; improve access 
and reduce barriers to medication-assisted treatments; and integrate screening for 
substance use and mental health disorders into primary care. This will help address 
issues related to prescription opioid as well as heroin misuse. 
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Table 2.1 Characteristics of Indiana's substance use treatment population, by year   
 2008 2009 2010 2011 2012 
Gender Male 12,897 
(67.5%) 
12,372 
(66.2%) 
17,287 
(63.7%) 
17,244 
(63.2%) 
15,717 
(62.8%) 
Female  6,214 
(32.5%) 
6,316 
(33.8%) 
9,837 
(36.3%) 
10,037 
(36.8%) 
9,309 
(37.2%) 
Age 12-20 years 2,716 
(14.2%) 
2,550 
(13.7%) 
3,592 
(13.2%) 
3,212 
(11.8%) 
2,926 
(11.7%) 
 21-34 years 9,272 
(48.6%) 
9,025 
(48.3%) 
13,048 
(48.1%) 
13,562 
(49.7%) 
12,457 
(49.8%) 
35-49 years 5,555 
(29.1%) 
5,450 
(29.2%) 
7,823 
(28.8%) 
7,723 
(28.3%) 
6,925 
(27.7%) 
50+ years 1,542 
(8.1%) 
1,663 
(8.9%) 
2,661 
(9.8%) 
2,784 
(10.2%) 
2,718 
(10.9%) 
Race White  14,937 
(78.2%) 
14,412 
(79.1%) 
20,505 
(79.3%) 
21,829 
(80.6%) 
20,277 
(81.0%) 
Black  3,118 
(16.3%) 
2,929 
(16.1%) 
4,051 
(15.7%) 
4,070 
(15.0%) 
3,774  
(15.1%) 
Other  1,056 
(5.5%) 
891 
(4.9%) 
1,298 
(5.0%) 
1,189 
(4.4%) 
973 
(3.9%) 
Ethnicity Hispanic  905 
(4.7%) 
771 
(4.3%) 
1,193 
(4.7%) 
1,212 
(4.8%) 
1,139 
(4.7%) 
Not Hispanic 18,206 
(95.3%) 
17,335 
(95.7%) 
24,040 
(95.3%) 
24,006 
(95.2%) 
23,070 
(95.3%) 
Reported 
Substance Use 
Alcohol 13,562 
(71.0%) 
12387 
(66.3%) 
16,093 
(59.3%) 
16,210 
(59.4%) 
14,853 
(59.4%) 
Marijuana 10,520 9,518 12,773 13,088 11,817 
  
 
1
9
 
 2008 2009 2010 2011 2012 
(55.1%) (50.9%) (49.1%) (48.0%) (47.2%) 
Cocaine 4,091 
(21.4%) 
3,389 
(18.1%) 
4,151 
(15.3%) 
4,513 
(16.5%) 
3,966 
(15.9%) 
Prescription Opioids 2,615 
(13.7%) 
2,571 
(13.8%) 
4,291 
(15.8%) 
5,337 
(19.6%) 
5,498 
(22.0%) 
Heroin 777 
(4.1%) 
1,015 
(5.4%) 
1,770 
(6.5%) 
2,658 
(9.7%) 
2,767 
(11.1%) 
Methamphetamine 1,757 
(9.2%) 
1,774 
(9.5%) 
2,633 
(9.7%) 
3,159 
(11.6%) 
3,018 
(12.1%) 
Benzodiazepines  1,153 
(6.0%) 
1,160 
(6.2%) 
1,791 
(6.6%) 
2,046 
(7.5%) 
2,002 
(8.0%) 
Other Drugs 801 
(4.2%) 
1,632 
(8.7%) 
4,326 
(16.0%) 
5,463 
(20.0%) 
4,994 
(20.0%) 
Polysubstance 
Use 
No drugs reported  31 
(0.2%) 
830 
(4.4%) 
2,643 
(9.7%) 
691 
(2.5%) 
276 
(1.1%) 
One drug reported 7,546 
(39.5%) 
7,048 
(37.7%) 
8,763 
(32.3%) 
9,388 
(34.4%) 
8,864 
(35.4%) 
Two drugs reported 6,760 
(35.4%) 
5,919 
(31.7%) 
7,753 
(28.6%) 
8,071 
(29.6%) 
7,186 
(28.7%) 
Three drugs reported 4,774 
(25.0%) 
4,891 
(26.2%) 
7,965 
(29.4%) 
9,131 
(33.5%) 
8,700 
(34.8%) 
Treatment 
Admissions 
 19,111 18,688 27,124 27,281 25,026 
Note: Since polysubstance use can and does occur, the individual drug categories are not mutually exclusive.  
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Table 2.2 Characteristics of Indiana’s substance use treatment population – overall, heroin users, and prescription opioid users  
 
Treatment Admissions Overall (includes all 
treatment episodes)  
Heroin Users Rx Opioid Users 
Gender Male 75,517 
(64.4%) 
5,262 
(58.6%) 
10,459 
(51.5%) 
Female  41,713 
(35.6%) 
3,725 
(41.5%) 
9,853 
(48.5%) 
Age 12-20 years 14,996 
(12.8%) 
1,074 
(12.0%) 
1,955 
(9.6%) 
21-34 years 57,364 
(49.4%) 
5,771 
(64.2%) 
12,896 
(63.5%) 
35-49 years 33,476 
(28.6%) 
1,581 
(17.6%) 
4,352 
(21.4%) 
50+ years 11,368 
(9.7%) 
560 
(6.2%) 
1,105 
(5.4%) 
Race White  91,960 
(79.8%) 
7,631 
(87.4%) 
18,643 
(93.4%) 
Black  17,942 
(15.6%) 
773 
(8.9%) 
609 
(3.1%) 
Other  5,407 
(4.7%) 
325 
(3.7%) 
714 
(3.6%) 
Ethnicity Hispanic  5,220 
(4.7%) 
421 
(5.2%) 
457 
(2.4%) 
Not Hispanic 106,657 
(95.3%) 
7,631 
(94.8%) 
18,513 
(97.6%) 
Reported 
Substance Use 
Alcohol 73,105 
(62.4%) 
1,873 
(20.8%) 
7,087 
(34.9%) 
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Treatment Admissions Overall (includes all 
treatment episodes)  
Heroin Users Rx Opioid Users 
Marijuana 57,716 
(49.2%) 
2,545 
(28.3%) 
8,285 
(40.8%) 
Cocaine 20,110 
(17.2%) 
2,265 
(25.2%) 
2,052 
(10.1%) 
Prescription Opioids 20,312 
(17.3%) 
2,060 
(22.9%) 
20,312 
(100.0%) 
Heroin 8,987 
(7.7%) 
8,987 
(100.0%) 
2,060 
(10.1%) 
Methamphetamine 12,341 
(10.5%) 
541 
(6.0%) 
2,090 
(10.3%) 
Benzodiazepines  8,152 
(7.0%) 
799 
(8.9%) 
3,651 
(18.0%) 
Other Drugs 17,216 
(14.7%) 
1,591 
(17.7%) 
2,729 
(13.4%) 
Polysubstance 
Use 
No drugs reported  4,471 
(3.8%) 
0 
(0.0%) 
0 
(0.0%) 
One drug reported 41,609 
(35.5%) 
1,855 
(20.6%) 
3,540 
(17.4%) 
Two drugs reported 35,689 
(30.4%) 
2,420 
(26.9%) 
4,959 
(24.4%) 
Three drugs reported 35,461 
(30.3%) 
4,712 
(52.4%) 
11,813 
(58.2%) 
IDU   10,062 
(8.6%) 
6,204 
(69.0%) 
3598 
(17.7%) 
Treatment 
Admissions 
 117,230 8,987 20,312 
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Table 2.3 Client characteristics associated with heroin use in Indiana’s substance use 
treatment population 
 
Effect N % Heroin Adjusted OR 
(95% Wald CL) 
p-
Value 
Prescription opioids 
     Used 
     Not used* 
 
20,312 
96,918 
 
10.1% 
7.2% 
 
1.18 (1.11-1.25) 
 
<.0001 
Gender  
     Female 
     Male*   
 
41,713 
75,517 
 
 
8.9% 
7.0% 
 
1.20 (1.15-1.26) 
 
<.0001 
Race  
     White  
     Black 
     Other* 
 
91,960 
17,942 
5,407 
 
8.3% 
4.3% 
6.0% 
 
1.53 (1.34-1.75) 
0.86 (0.74-1.01 
 
<.0001 
.0610 
 
Hispanic  
     Yes 
     No* 
 
5,220 
106,65
7 
 
8.1% 
7.2% 
 
1.18 (1.06-1.31) 
 
.0035 
Age  
     12-20 
     21-34 
     35-49 
     50 and up* 
 
14,996 
57,364 
33,476 
11,368 
 
7.2% 
10.1% 
4.7% 
4.9% 
 
1.43 (1.28-1.60) 
1.93 (1.76-2.12) 
0.89 (0.80-0.99) 
 
<.0001 
<.0001 
.0307 
Year of admission Δ 
     2008 
     2009 
     2010 
     2011 
     2012 
 
19,111 
18,688 
27,124 
27,281 
25,026 
 
4.1% 
5.4% 
6.5% 
9.7% 
11.1% 
1.31 (1.28-1.33) <.0001 
* Reference groups (OR=1.00)  
Δ Year of treatment admission was entered as a continuous variable in the logistic 
regression analysis.  
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Table 2.4 Age of first heroin and prescription opioid use among clients receiving substance use treatment in Indiana  
 
 Age of first heroin use 
(dual use with Rx opioids) 
Age of first Rx opioid use 
(dual use with heroin) 
Age of first heroin use 
(no Rx opioid use) 
Age of first Rx opioid 
use (no heroin use) 
11 and under 14 (1.0%) 250 (1.8%) 75 (1.5%) 236 (1.9%) 
12-14 43 (3.0%) 1,127 (8.3%) 296 (6.1%) 1,003 (8.0%) 
15-17 182 (12.7%) 3,089 (22.7%) 879 (18.0%) 2,758 (21.9%) 
18-20 372 (25.9%) 3,099 (22.7%) 1,278 (26.2%) 2,830 (22.5%) 
21-24 348 (24.3%) 2,285 (16.8%) 968 (19.8%) 2,132 (16.9%) 
25-29 267 (18.6%) 1,691 (12.4%) 768 (15.7%) 1,608 (12.8%) 
30-34 117 (8.2%) 908 (6.7%) 334 (6.9%) 789 (7.0%) 
35-39 57 (4.0%) 539 (4.0%) 158 (3.2%) 523 (4.2%) 
40-44 19 (1.3%) 338 (2.5%) 66 (1.4%) 331 (2.6%) 
45-49 10 (0.7%) 183 (1.3%) 35 (0.7%) 184 (1.5%) 
50-54 4 (0.3%) 91 (0.7%) 15 (0.3%) 97. (0.8%) 
55 and above 1 (0.1%) 31 (0.2%) 7 (0.1%) 26 (0.2%) 
 
 
  
  
24 
 
 
Figure 2.1 Trend in Indiana substance use treatment admissions with observed and 
predicted heroin and prescription opioid use Figure 2 
 
  
2008 2009 2010 2011 2012
Heroin obs 4.1% 5.4% 6.5% 9.7% 11.1%
Heroin pred 4.1% 5.4% 6.9% 9.0% 11.5%
Rx opioids obs 13.7% 13.8% 15.8% 19.6% 22.0%
Rx opioids pred 12.6% 14.6% 16.7% 19.1% 21.7%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
Observed vs. Predicted Heroin & Rx Opioid Abuse
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CHAPTER 3 Assessment of Risk Behaviors in Patients with Opioid Prescriptions: A Study 
of Indiana’s INSPECT Data 
3.1.  Specific Aim #2 
Chapter 3 addresses the Specific Aim #2, as outlined in the abstract.  The 
purpose is to Analyze 2014 INSPECT (Indiana’s prescription drug monitoring program) 
data to identify factors that increase patients’ likelihood to engage in opioid-related risk 
behaviors.  
3.2.  Introduction 
Prescription opioid misuse is a widely recognized public health problem.12,22,63,75  
Factors that possibly contributed to the epidemic include increased availability of 
prescription opioids, social acceptability of using medications for nonmedical purposes, 
and aggressive marketing by the pharmaceutical industry.18,21,29,38,76,77 There are 
considerable geographic differences in opioid prescribing rates among states,78 which 
cannot be solely explained by variations in pain prevalence, but may reflect a lack of 
consensus on the appropriate use of opioids in the treatment of chronic non-cancer 
pain, patients’ increasing demands for opioids, and regional differences in rates of 
opioid diversion.79 A direct relationship between the rise in opioid prescribing, often out 
of a concern to avoid undertreatment of pain,24 and the increase in opioid-related 
adverse events has been demonstrated.12,80  
One chief strategy to curb prescription drug misuse is prescription drug 
monitoring programs (PDMPs). These statewide electronic surveillance programs gather 
information from pharmacies each time a controlled substance is dispensed. Thus, 
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PDMPs can serve as monitoring tools, tracking potential misuse and diversion of 
controlled substances, as well as clinical tools, assisting healthcare providers in decision-
making processes. Sajid et al.81 have shown that in a clinical setting, PDMPs can be 
utilized as a tool to measure treatment outcomes in opioid addiction.  
Evidence suggests that PDMPs are effective in addressing the prescription drug 
epidemic by identifying “questionable activity” (e.g., doctor- and pharmacy-shopping, 
prescription fraud, problematic prescribing), aiding clinical decision-making prior to 
prescribing or dispensing controlled substances, and tracking trends in providers’ 
prescribing patterns.82 Even though PDMPs are considered highly effective, they remain 
a largely underutilized resource to improving public health outcomes.82  
One of the challenges in using PDMPs to screen for questionable or high-risk 
activity has been the lack of standardized criteria on how to define these concepts. 
Various measures and thresholds have been suggested; however, little commonality 
exists in the criteria used by individual state PDMPs to identify risk patterns concerning 
patients (e.g., doctor-shopping) or healthcare professionals (e.g., inappropriate 
prescribing).83,84 In addition, setting the proper thresholds of these measures is also a 
difficult task. Just as with any diagnostic procedure, low thresholds will result in a more 
sensitive screening process identifying higher numbers of potential misusers, but also 
lead to more false-positive determinations. Such misclassification is likely to stigmatize 
patients, overwhelm healthcare providers trying to make clinically sound decisions, and 
burden the criminal justice system in their efforts to control diversion. On the other 
hand, setting high thresholds will reduce the number of patients being flagged for 
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questionable activity, but also fail to identify individuals who may be at risk for opioid-
related adverse events (false negatives) and who would benefit from clinical 
interventions.   
Chronic opioid therapy for non-cancer pain is controversial and high doses of 
prescribed opioids may place patients at risk for overdoses and other adverse events.85 
Several current clinical practice guidelines on treating adults with chronic pain advise 
against using doses higher than 90-200 morphine milligram equivalents (MMEs) or 
combining opioids and benzodiazepines.86 Researchers found that daily doses of 100 
MMEs or more significantly increased the risk of overdose,87 linking it to an eleven-fold 
increase in overdose-related mortality.88  Visiting multiple healthcare providers and/or 
pharmacies has also been associated with overdose deaths. A study found that seeing 
four or more prescribers or obtaining opioids from four or more pharmacies increased 
the risk of opioid-related mortality about six-fold.88 Benzodiazepines are generally safe 
unless taken in combination with opioids, as their combined effects produce significant 
respiratory depression.89 According to one study, most overdose deaths attributable to 
benzodiazepines also involved other drugs, primarily opioids (71%).90 Due to the 
concern of these opioid-related adverse events, the Centers for Disease Control and 
Prevention (CDC) recently published comprehensive guidelines for prescribing opioids 
for chronic pain: identifying high MMEs, multiple providers, and concurrent use of 
opioids and benzodiazepines as major concerns.31  
The purpose of this study was to utilize Indiana’s PDMP database to identify 
patient and prescription characteristics that are highly associated with opioid-related 
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risk behaviors. Findings from this study may aid in the clinical decision-making process 
and help more appropriately identify those who are at risk and would benefit from 
possible treatment or intervention. 
3.3.  Methods 
3.3.1.  Data Sources 
This study utilized de-identified data from the Indiana Scheduled Prescription 
Electronic Collection and Tracking (INSPECT) program, which is Indiana’s PDMP.91 Each 
time a controlled substance (schedules II through V) is dispensed in Indiana, pharmacies 
are mandated to submit key information, including patient, prescriber, pharmacy, and 
drug characteristics, electronically to the INSPECT database. Since this project utilized 
previously collected data devoid of identifying information, institutional review board 
approval was not needed.  
INSPECT data from 2014 were analyzed for this study. The complete dataset 
contained 13,066,666 observations with each observation representing the dispensation 
of a controlled substance. Drug categories and daily dosages of MMEs for opioids were 
determined based on the 11-digit National Drug Code (NDC).  From these data, a total of 
1,419,160 dispensations (10.9%) with missing or invalid NDC were excluded from the 
analyses, resulting in a dataset with 11,647,506 observations. All individuals receiving an 
opioid prescription in 2014 were included in the primary analyses. The number of 
unique individuals who filled at least one prescription for an opioid medication was 
1,538,120.  
3.3.2.  Variables  
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INSPECT variables of interest included patient characteristics (gender, age), drug 
information (NDC, quantity, and number of days supplied), date when the drug was 
dispensed, as well as prescriber and pharmacy information. Identification (ID) numbers 
were assigned to each patient, prescriber, and pharmacy. These ID numbers were 
scrambled for de-identification and cannot be traced back to individuals or facilities.  
Using a conversion syntax from the CDC, controlled substances were coded as 
opioids, benzodiazepines, or other pharmaceuticals, and daily dosages of MMEs for 
opioids were computed.92  
3.3.3.  Definition of High-Risk Activity 
The outcomes of interest for this study were high-risk behaviors among patients 
using opioids. Rather than focusing on only one behavior associated with opioid-related 
adverse events, several were examined. Based on a review of existing literature and in 
line with CDC guidelines, the following activities have been associated with opioid-
adverse events, particularly overdoses, and were examined in this study:31,86-88 (1) 
consuming large daily doses of opioids >90 MME per opioid prescription; (2) obtaining 
prescriptions for opioids from four or more prescribers within the 12-month period; (3) 
receiving opioids from four or more pharmacies within the 12-month period; and (4) 
using opioids and benzodiazepines concurrently (both prescriptions having been filled 
within the same calendar month) at least once during the year.   
3.3.4.  Analyses  
Descriptive statistics were employed to summarize the study population and 
examine the distribution of individual risk behaviors that, according to the literature, 
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have been linked to opioid-related adverse events.  
Three logistic regression analyses were conducted to identify factors that 
increased patients’ likelihood to engage in high-risk behaviors: (1) binary logistic 
regression analysis to assess the probability of patients engaging in at least one of the 
four risk behaviors (i.e., receiving any one opioid prescription >90 MME; having 4 or 
more opioid prescribers; having 4 or more opioid dispensers; concurrently using opioids 
and benzodiazepines) versus not engaging in any of these four high-risk activities;  (2) 
ordinal (cumulative) logistic regression analysis to predict the odds of being in a higher 
risk behavior category (i.e., engaging in more risk behaviors) in a multi-level – ordinal – 
outcome (0 through 4 risk behaviors); in this model, the cumulative logit represents a 
summary of the odds ratios obtained from separate binary logistic regressions of the 
ordered multi-level outcome;93 and (3) binary logistic regression analysis to predict the 
likelihood of patients engaging in all four risk behaviors versus engaging in less than all 
the behaviors or none at all.   
Independent variables in all three analyses included gender and age category of 
each patient, as well as annual dispensation of opioids, benzodiazepines, and other 
controlled substances (i.e., all controlled prescription drugs Schedules II-V, except 
opioids and benzodiazepines; may include stimulants such as Ritalin, barbiturates such 
as Phenobarbital, anticonvulsants such as Lyrica, etc.). The latter variables were 
converted into categories for the analyses, because the continuous distributions were 
highly positively skewed (there was a small but non-negligible number of individuals in 
the database with extremely high levels of annual dispensation of opioids, which 
  
31 
 
 
prevented analyses based on models which assume a symmetric bell-shaped-like 
distribution of the measurements).  
Opioids, the focus of this study, were categorized to represent average monthly 
prescriptions; e.g., 1 to 12 annual opioid dispensations represented “up to one monthly 
prescription,” 13 to 24 dispensations, “up to two monthly prescriptions,” etc., since a 
one-month supply is usually provided with each prescription. Prescriptions of 
benzodiazepines and other controlled substances were converted into binary categories 
(0 or 1 benzodiazepine prescription per year vs. 2 or more; 1 to 12 other controlled 
substances per year vs. more than 12). While concurrent use of opioids and 
benzodiazepines was one of the study’s outcomes, having a benzodiazepine prescription 
did not necessarily imply co-use of both pharmaceuticals; this was only the case if both 
prescriptions were filled within the same calendar month. Also, having additional opioid 
prescriptions did not automatically add to a patient’s MME, since MME was calculated 
per prescription and not as a cumulative measure.   
Receiver operating characteristic (ROC) curves were plotted and the areas under 
the ROC curves (AUCs) were calculated for the two binary logistic regression analyses 
(analyses 1 and 3) to measure the accuracy of the independent variables in detecting 
high-risk activity.94 Lastly, chi-square tests were used to examine if the AUC from the full 
model was superior to the individual AUCs.   
Whenever appropriate, odds ratios and 95% Wald confidence intervals were 
computed. All analyses were conducted using Statistical Analysis Software SAS® version 
9.4 (SAS Institute, Cary, NC). Results with p-values less than 0.05 were deemed 
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significant.  
3.4.  Results 
3.4.1.  Description of Study Population 
The INSPECT database documented that more than 6.2 million (53.9%) of the 
11.6 million pharmaceuticals dispensed in 2014 were opioids and nearly 3 million 
(25.1%) were benzodiazepines. While the vast majority of patients were Indiana 
residents, a small percentage (2.3%) were out-of-state residents. About one-tenth 
(11.3%) of prescriptions were paid for privately and the rest were covered by health 
insurance. The most frequently dispensed opioids were hydrocodone (59.7%) and 
oxycodone (16.0%). The distribution of MME was positively skewed (median=33.8; 
interquartile range [IQR]=39.2).  
A little more than half of the 1,538,120 patients were female (57.0%) and the 
majority (70.4%) was over the age of 35 (Table 3.1). The number of opioid dispensations 
(median=2.0; IQR=3.0) and maximum MMEs (median=37.5; IQR=31.3) per patient was 
highly skewed, as was the number of unique opioid prescribers (median=1.0; IQR=1.0) 
and dispensers (median=1.0; IQR=0.0).   
3.4.2.  Distribution of Risk Behaviors 
Three quarters of the patients (74.4%) did not fall in any of the risk categories; 
i.e., they did not receive high daily doses of opioids, did not visit multiple providers or 
dispensers, or engage in polypharmacy of opioids and benzodiazepines. However, 8.4% 
of patients obtained at least one prescription with a daily dose exceeding 90 MME (for 
some patients, daily doses >90 MME occurred multiple times throughout the year); 
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6.5% visited 4 or more different opioid prescribers; 3.1% obtained their opioids from 4 
or more pharmacies; and 17.2% concurrently used opioids and benzodiazepines. 
Furthermore, a small number of patients were at the extreme end of the spectrum, 
obtaining exceptionally high doses of opioids, visiting a large number of prescribers and 
pharmacies, and concurrently using opioids and benzodiazepines for most of the year 
(Table 3.1).  
The study assessed the distribution of risk behaviors, from 0 (no risk behaviors 
present) to 4 (all four risk behaviors present).  While most of Indiana’s patients with 
opioid prescriptions (74.4%) did not exhibit any of the risk behaviors, 18.4% presented 
with one, 5.3% with two, 1.6% with three, and 0.4% with all four risk behaviors (Table 
3.1).  
3.4.3.  Predictors of High-Risk Activity 
Results of the logistic regression analyses (Models 1 through 3) showed the 
following: 
Model 1: Findings from the multiple logistic regression analysis indicated that 
having at least one risk behavior present was significantly associated with the annual 
number of prescriptions (opioids, benzodiazepines, or other pharmaceuticals). 
Averaging up to two opioids per month (i.e., 13 to 24 prescriptions for the year), as 
opposed to only up to one monthly opioid (i.e., 1 to 12 annual prescriptions; reference 
group) increased the patients’ odds to engage in at least one risk behavior 11-fold (odds 
ratio [OR]=11.36; 95% confidence interval [CI]: 11.16-11.55).  In fact, averaging more 
than four pain relievers per month (i.e., 49 or more during the year) resulted in an 80-
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fold increase in the odds of engaging in at least one risk behavior (OR=80.26; 95% CI: 
64.65-99.64). Furthermore, receiving two or more benzodiazepines during the year was 
associated with a nearly 36-fold increase in the odds of engaging in at least one risk 
behavior (OR=35.91; 95% CI: 35.43-36.39) compared to having zero or only one annual 
benzodiazepine prescription. Averaging more than one monthly prescription of other 
controlled substances increased the odds by 31 percent (OR=1.31; 95% CI: 1.25-1.38).  
Adults, especially those ages 36 to 55, were more likely to engage in one or more risk 
behavior than younger patients (Table 3.2).    
To investigate the accuracy of the predictor variables in detecting high-risk 
activity, an ROC analysis was conducted. The ROC results showed that the AUCs of all 
predictor variables individually were significantly greater than 0.5 (p-values < .0001) and 
that the full model was superior in discriminating between patients who engaged in at 
least one high-risk activity and those who did not (AUC= .9281; p<.0001) (Figure 3.1).  
Model 2: The cumulative (ordinal) logistic regression analysis indicated a 
significant relationship between the rising number of dispensations and increasing 
number of risk behaviors in patients. Compared to patients averaging only up to one 
monthly opioid prescription, those receiving up to two opioid prescriptions per month 
increased their odds of engaging in more risk behaviors almost 10-fold (OR=9.67; 95% 
CI: 9.55-9.80); each additional monthly prescription added to the odds, leading to a 
nearly 53-fold increase in patients averaging more than four opioids per month 
(OR=52.78; 95% CI: 48.12-57.89). Additionally, receiving more than one annual 
benzodiazepine prescription raised the odds that patients would fall into a higher risk-
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behavior category more than 20-fold (OR=20.67; 95% CI: 20.45-20.89). Averaging more 
than one monthly prescription of other controlled substances added an additional 9 
percent to the odds (OR=1.09; 95% CI: 1.05-1.13). Adults aged 36 to 55 years had the 
highest odds of engaging in more risk behaviors than any of the other age groups (Table 
3.2).    
Model 3: For the third analysis, a multiple logistic regression was utilized to 
model the probability of having all four risk behaviors present. More opioid and 
benzodiazepine prescriptions were linked to higher odds of engaging in all four risk 
behaviors, while greater dispensation of other controlled substances did not have a 
significant impact on this outcome. Averaging up to four monthly opioid prescriptions 
was associated with the highest increase (OR=68.55; 95% CI: 59.25-79.30) in this model 
and having two or more annual benzodiazepine prescriptions also raised the odds of 
engaging in all four risk behaviors 13-fold (OR=12.98; 95% CI: 12.00-14.04). Both being 
18 to 35 years old and being male increased the odds of engaging in all four risk 
behaviors (Table 3.2).  
Based on findings from the ROC analysis, the predictor variables were highly 
accurate in detecting patients who engaged in all four risk behaviors (AUC=.9528; 
p<.0001) (Figure 3.2). 
3.5.  Discussion 
More than 6.2 million opioids were dispensed in Indiana in 2014, enough to 
provide nearly one prescription for every resident in the state (population in 2014 was 
6,596,855). The majority of patients did not fall into any of the identified risk categories; 
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yet a substantial number of individuals did exhibit a range of behaviors that potentially 
could lead to opioid-related adverse events. Only a small percentage (0.4%) of all 
patients were on the extremely high-end of the risk spectrum; however, these 
individuals would most likely benefit from clinical interventions to prevent negative 
opioid-related consequences.  
This study tested three outcomes linked to opioid-related risk behaviors. These 
outcomes were modeled from least (one or more risk behaviors were present) to most 
severe (all four risk behaviors were present). Findings from the analyses all pointed 
toward the same general conclusions: (1) increasing the number of opioid prescriptions 
and (2) adding an even fairly small number of benzodiazepine prescriptions substantially 
increased a patient’s likelihood to engage in opioid-related risk behaviors. For 
healthcare professionals, this means that prescribing, on average, a second monthly 
opioid can increase the patient’s risk by a factor of 10 or more (depending on the 
model) and each additional monthly opioid prescription would add significantly to the 
risk. Similarly, prescribing two or more benzodiazepines annually represents at least a 
13-fold risk increase among patients who have had one or more opioid prescriptions in 
the same year. Risk behaviors were least likely to occur in young patients under the age 
of 18 and primarily associated with adults aged 36 to 55. Gender did not seem to play 
much of a role, except for Model 3, which showed that male patients were more likely 
to engage in all four risk behaviors compared to their female counterparts.  Though only 
one-fourth of patients engaged in one or more risk behaviors, this group obtained over 
half of all opioid prescriptions and opioid consumption proportionally rose with 
  
37 
 
 
increasing number of risk behaviors.  
Other studies observed similar associations between the number of prescriptions 
and risk behaviors, such as having 12 or more opioid prescriptions per year more than 
doubled the risk for prescription opioid misuse;95 an increasing number of prescriptions 
was associated with doctor- and pharmacy-shopping;96 and higher numbers of 
prescriptions, especially for opioids or benzodiazepines, increased the risk of drug-
related mortality.88,96  
However, to my knowledge this is the only study that incorporated multiple 
models to measure the association between prescription drug dispensations and opioid-
related risk behaviors using PDMP data. Furthermore, it is important to note that the 
AUCs for both models were above 0.9, reflecting the models’ excellent accuracy in 
discriminating between patients who engaged in opioid-related risk activities and those 
who did not.  
3.5.1.  Strengths and Limitations of the Study 
A strength of the current study was its large sample size (n=1,538,120 unique 
opioid patients) and completeness of the dataset, since submission to INSPECT in 2014 
was mandatory within a seven-day time frame. Several limitations were noted. 
Concurrent use of opioids and benzodiazepines was one of the study’s outcomes. 
Though a prescription of benzodiazepines did not automatically imply concurrent use, 
78% of the nearly 340,000 patients with a benzodiazepine script had both opioid and 
benzodiazepine prescriptions filled within the same month and suggested concurrent 
use. 
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Computation of the daily dose MME was not a cumulative measure, but instead 
was based on any one opioid prescription throughout the year. While it is a limitation 
that the overall or accumulated MME was not computed for any given period, this was 
necessary to circumvent circularity, since the number of opioid prescriptions 
(independent variable) would have automatically increased MME.   
PDMPs identify prescribers by their individual Drug Enforcement Agency (DEA) 
number. Patients who see multiple providers at the same clinic may be inappropriately 
marked as “doctor-shoppers,” because the database is unable to recognize when 
providers are working together.84 Another limitation is that Indiana’s PDMP is currently 
not connected to any other database; i.e., prescription drug history cannot be directly 
linked to health or other outcomes and the risk identified by these analyses cannot be 
correlated with any clinical outcomes. Furthermore, no information was available on 
patients’ mental health or smoking status, both of which have been identified as strong 
risk factors for substance misuse behaviors.72 It is also important to note that the study’s 
findings are specific to Indiana and may not be generalizable to other states. 
3.5.2.  Conclusion   
Prescribing at least two monthly opioids, on average, significantly increased 
patients’ odds to engage in opioid-related risk behaviors, as did the prescription of two 
or more benzodiazepines per year. Only a small percentage of opioid patients fell into 
the highest category of risk behaviors. However, these patients comprised nearly 5,000 
Indiana residents potentially at risk for opioid-related problems, such as opioid use 
disorders, respiratory depression, overdoses, or diversion.   
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Findings from this study are relevant to the clinical decision-making process and 
could be used to improve provider-patient communication by encouraging healthcare 
professionals to routinely utilize INSPECT prior to prescribing controlled substances, to 
educate patients on the risks and benefits of using and abusing opioids by themselves as 
well as with other controlled substances, and to better screen patients for symptoms of 
opioid use disorders, particularly those at high-risk. PDMPs have the potential to be a 
crucial element in the nation’s response to the prescription drug epidemic. Continued 
national and state-level funding is essential to maintain and expand the states’ capacity 
to develop and use PDMP data, allow for data-sharing across state lines, and integrate 
PDMP data with other databases, such as electronic health records.   
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Table 3.1 Patient characteristics and distribution of risk behaviors among unique patients with at least one opioid prescription ble 5 
Number of unique opioid patients 
          Female 
 1,538,120 
876,870 (57.0%) 
Age Group 
 
0-17 years 
18-35 years 
36-55 years 
56 and older 
71,078 (4.6%) 
384,719 (25.0%) 
510,767 (33.2%) 
571,556 (37.2%) 
Maximum MME *Max MME < 90 
Max MME between 90-200 
Max MME between 200-500 
Max MME > 500 
1,408,991 (91.6%) 
10,148 (6.6%) 
24,191 (1.6%) 
3,322 (0.2%) 
High daily doses of opioids  
(number of times patient has received 
MME > 90) 
*0 
1-12 
13+ 
1,408,991 (91.6%)  
111,312 (7.2%) 
17,689 (1.2%) 
Multiple opioid prescribers 
(number of opioid prescribers per patient) 
*1-3  
4-10  
11+ 
1,438,345 (93.5%) 
97,957 (6.4%) 
1,818 (0.1%) 
Multiple opioid dispensers 
(number of pharmacies from which patient 
has obtained opioids)  
*1-3  
4-10  
11+ 
1,490,302 (96.9%) 
47,383 (3.1%) 
435 (0.0%) 
Co-use of opioids and benzodiazepines 
(number of months in which co-use 
occurred) 
*0 
1-6 
7-12 
1,272,616 (82.7%) 
208,130 (13.5%) 
57,374 (3.7%) 
Number of risk behaviors present  
 
*0 
1 
2 
3 
4 
1,143,604 (74.4%) 
282,811 (18.4%) 
81,224 (5.3%) 
25,085 (1.6%) 
5,396 (0.4%) 
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Note: Unit of analysis is the individual patient. 
*No risk behavior. 
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Table 3.2. Predictors of opioid-related risk behaviors, Models 1 – 3 Table 6 
  Model 1: Probability of 
engaging in at least one risk 
behavior (binary outcome) 
Model 2: Probability of falling 
into a higher risk-behavior 
category (ordinal outcome) 
Model 3: Probability of 
engaging in all 4 risk 
behaviors (binary 
outcome) 
Effect  Adjusted OR  
(95% Wald CI) 
Adjusted OR 
(95% Wald CI) 
Adjusted OR 
(95% Wald CI) 
Opioid 
prescriptions  
1-12 
13-24 
25-36 
37-48 
49+ 
REF 
11.36 (11.16-11.55) 
33.54 (31.82-35.36) 
52.79 (44.97-61.97) 
80.26 (64.65-99.64) 
REF 
9.67 (9.55-9.80) 
29.76 (28.92-30.63) 
49.01 (45.54-52.74) 
52.78 (48.12-57.89) 
REF 
14.66 (13.60-15.79) 
40.11 (36.76-43.76) 
68.55 (59.25-79.30) 
57.86 (47.45-70.56) 
Benzodiazepine 
prescriptions 
0-1 
2+ 
REF 
35.91 (35.43-36.39) 
REF 
20.67 (20.45-20.89) 
REF 
12.98 (12.00-14.04) 
Other 
prescriptions 
0-12 
13+ 
REF 
1.31 (1.25-1.38) 
REF 
1.09 (1.05-1.13) 
REF 
0.95 (0.83-1.09) 
Gender  Female 
Male  
REF 
1.01 (1.00-1.02) 
REF 
1.04 (1.03-1.04) 
REF 
1.29 (1.22-1.36) 
Age group  0-17 years 
18-35 years 
36-55 years 
56 years & older 
REF 
2.69 (2.59-2.79) 
3.41 (3.28-3.53) 
3.21 (3.09-3.33) 
REF 
2.93 (2.83-3.04) 
3.42 (3.30-3.54) 
3.17 (3.06-3.28) 
REF 
2.47 (1.56-3.90) 
1.58 (1.00-2.49) 
1.10 (0.70-1.74) 
  P<.0001 P<.0001 P<.0001 
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Figure 3.1. ROC and AUC for Model 1 (at least one risk behavior present) Figure 3 
 
 
Figure 3.2. ROC and AUC for Model 3 (all four risk behaviors present) Figure 4 
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CHAPTER 4 The Ongoing Rise in Neonatal Abstinence Syndrome (NAS) Across the U.S. 
4.1.  Specific Aim #3 
 Chapter 4 addresses the Specific Aim #3, as outlined in the abstract.  The 
purpose is to review U.S. trends in neonatal abstinence syndrome (NAS) incidence from 
2008-2014, measure regional variability, and identify personal and environmental risk 
factors associated with NAS. 
4.2.  Introduction 
The opioid epidemic significantly contributes to the nation’s disease burden,97 
accounting for more than 33,000 overdose deaths in 2015.98 U.S. prevalence rates of 
opioid misuse have increased substantially in recent years,2,99 including among pregnant 
women.14 The rise in misuse and overdose deaths has often been linked to increasing 
sales and availability of opioids.20,21 According to data from the 2013 National Survey on 
Drug Use and Health (NSDUH), 5.4% of pregnant women ages 15 to 44 years used an 
illicit substance in the past month, of which an estimated 15,000 pregnant women 
reported misusing prescription opioids (pain relievers) and 4,000 indicated heroin 
use.100 Furthermore, antepartum maternal opioid use increased from 1.2 mothers per 
1,000 live births in 2000 to 5.6 mothers per 1,000 live births in 2009.14 With the increase 
in opioid misuse, the country has also seen a rise in the incidence of neonatal 
abstinence syndrome (NAS).15   
NAS, also called neonatal withdrawal, is a direct response in the newborn infant 
to the abrupt discontinuation of chronic intrauterine exposure to drugs and other 
substances used by the mother during pregnancy. Clinical features of NAS include 
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tremors, irritability, excessive high-pitched crying, difficulty sleeping, poor feeding, poor 
weight gain, dehydration, vomiting, diarrhea, and in severe cases, seizures.13,101-103 The 
onset, duration, and severity of NAS is determined by drug characteristics, including 
type, dosage, and pharmacological properties; by maternal drug history and 
metabolism; by infant metabolism and excretion; as well as other factors.13,101 While 
various drugs can lead to NAS, opioids are the most common cause of neonatal 
withdrawal.101 Before the 1970s, morphine or heroin were the predominant reasons for 
the development of the condition, but in recent years, this has changed to include all 
opioids, prescribed and illegal.13 Even methadone or buprenorphine used as part of a 
medication-assisted treatment (MAT) program can result in NAS; however, 
comprehensive MATs together with prenatal care are accepted as the standard-of-care 
for pregnant women with opioid addiction104,105 and can improve health outcomes for 
both mother and child.106-108 
According to studies by Patrick et al., the rate of newborns diagnosed with NAS 
rose from 1.2 per 1,000 hospital births in 2000 to 5.8 in 2012, reflecting a nearly 400-
percent rate increase.14,15 Although the duration of NAS is relatively short109,110 and 
long-term effects on brain development are largely unknown,13,111 the health care costs 
associated with the condition are substantial. Hospitalization in neonatal intensive care 
units are expensive and can disrupt infant-family attachment.112 Hospital charges in the 
United States due to NAS more than doubled from $720 million in 2009 to $1.5 billion in 
2012, often disproportionally affecting those with lower socio-economic status since 
infants born with NAS were more likely to be covered by Medicaid and to mothers who 
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reside in poorer neighborhoods.14,15  
Since the prevalence of NAS has increased consistently in recent years and the 
costs of caring for infants with the condition has also risen substantially, more specific 
information is needed to better understand the epidemiology of NAS cases. The purpose 
of this study was to build on previous research by: (1) examining trends in the national 
NAS incidence from 2008 through 2014; (2) measuring regional variability in NAS 
incidence; and (3) identifying personal and environmental risk factors associated with 
the occurrence of the syndrome. 
4.3.  Methods  
4.3.1.  Study Design and Data Source 
Infants with NAS were identified through a retrospective cross-sectional analysis 
of data from the National Inpatient Sample (NIS) for 2008 through 2014.113 NIS is part of 
the Agency for Healthcare Research and Quality’s (AHRQ) Healthcare Cost and 
Utilization Project (HCUP). It is the largest publicly available all-payer inpatient health 
care database in the United States and yields national estimates of hospital inpatient 
stays. NIS records include patient demographics, diagnosis and procedure codes, 
hospital characteristics, length of stay, total charges, and expected payment source. The 
NIS dataset initially contained a sample of U.S. hospitals with all discharges from these 
hospitals. Since 2012, however, NIS has been comprised of a sample of discharges from 
all HCUP-participating hospitals in the U.S. The new design enables more precise and 
stable national estimates. Due to the redesign, a one-time decrease in the historical 
trends for discharge counts was expected in the 2012 statistics. Since this study spans 
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from 2008 through 2014, the analyses utilized AHRQ’s trend discharge weights to 
minimize the effects of the redesign on estimated trends that cross the 2012 data 
year.114  
The NIS datasets used for this study contained over 53 million hospital 
discharges from 2008 through 2014, including 5,538,204 hospital births. This study 
utilized secondary non-identified information and was, therefore, exempt from review 
of the Indiana University Institutional Review Board.  
4.3.2.  Identification of Cases 
NAS was defined as having ICD-9 codes of 779.5 (drug withdrawal syndrome in 
newborn) or 760.72 (narcotics affecting fetus or newborn via placenta or breast milk), or 
ICD-10 codes of P96.1 (neonatal withdrawal symptoms from maternal use of drugs of 
addiction), P96.2 (withdrawal symptoms from therapeutic use of drugs in newborn), or 
P04.49 (newborn affected or suspected to be affected by maternal use of other drugs of 
addiction) in any of the 15 discharge diagnosis fields. 
4.3.3.  Personal and Environmental Factors 
Personal characteristics of the infant (gender, race) as well as demographic 
information of the mother (geographic location of residence, household income, and 
primary insurance type) were available from the NIS datasets and included in the 
analyses.  
Environmental factors included the regional drug overdose fatality rate, which 
provided a severity indicator of opioid misuse in the geographic region. Mortality rates 
attributable to drug poisoning (ICD-10: X40-X44, X60-X64, X85 or Y10-Y14) were 
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aggregated for the nine U.S. Census divisions for each year of the study from 2008 
through 2014.115 
Opioid use among pregnant women was of particular interest since it is the 
primary risk factor for NAS. Using substance abuse treatment data from the Substance 
Abuse and Mental Health Services Administration (SAMHSA),116 annual rates of 
treatment admissions for opioid misuse in women aged 15 to 44 years were computed. 
These rates were aggregated for the nine U.S. Census divisions for each year, 
categorized into quartiles, and then included in the model with a one-year lag; i.e., 
treatment admission rate quartiles from 2007 were added as independent variables for 
2008 NAS outcomes, etc. All women of childbearing age were included, not just 
pregnant women, in the treatment rate for several reasons. Given that 86% of 
pregnancies are estimated to be unintended among women who misuse opioids,117 
some women may not be aware of their pregnancy status and, therefore, not report 
being pregnant at the time of treatment admission. Also, since we included a one-year 
lag, women who were not pregnant when they entered treatment may have become so 
within the next year.    
4.3.4.  Analyses 
Individual characteristics and outcomes related to hospital stays for infants with 
NAS were compared to those without a NAS diagnosis.  National NAS incidence rates 
were calculated for each year by dividing the number of infants with a NAS diagnosis by 
the total number of hospital births, expressed per 1,000 births. To measure regional 
variability, NAS incidence rates from 2012 through 2014 were compared among the nine 
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U.S. Census divisions.  
Both bivariate and multivariate logistic regression analyses were performed to 
test the association between personal and environmental risk factors and the likelihood 
of an infant being born with neonatal withdrawal as well as to assess NAS trends over 
time. The multivariate analysis produced adjusted odds ratios, taking potential personal 
and environmental confounders into account, while the bivariate analyses provided 
crude or unadjusted odds ratios. 
For relevant analyses, weights provided by HCUP were applied to enable 
nationally representative estimates to be made with confidence. Odds ratios and 95% 
Wald confidence intervals were computed and included in the results. All analyses were 
conducted using Statistical Analysis Software SAS® version 9.4 (SAS Institute, Cary, NC). 
Results with p-values less than 0.05 were deemed significant.  
4.4.  Results 
4.4.1.  Description of Study Population 
During the study period, 33,230 infants were discharged with a diagnosis of NAS. 
Compared to all other births, infants with a diagnosis of neonatal withdrawal were more 
likely to be male, white, from households with lower income, and covered by Medicaid 
as the primary payer. Most hospital births (NAS and other) occurred in urban, 
population-dense areas; however, NAS incidence rates were higher in rural areas (Figure 
4.1). 
 During the 7-year period, infants with NAS had significantly longer average 
length of stays (13.6 days vs. 3.3 days; p < .01), higher mean number of comorbid 
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medical conditions (6.1 vs. 3.0; p < .01), and accumulated more average total charges 
($50,415 vs. $11,027; p < .01) as shown in Table 4.1. 
4.4.2.  Annual NAS Incidence Rates 
The national annual NAS incidence rate nearly tripled from 3.1 (95% CI: 3.0-3.2) 
per 1,000 births in 2008 to 9.1 (95% CI: 8.8-9.3) per 1,000 births in 2014 (p for trend < 
.01), as can be seen in Figure 4.2. Rates varied regionally, but the trend pattern 
remained the same. Particularly high rates and steep increases were seen in the U.S. 
Census divisions of East South Central (Kentucky, Tennessee, Mississippi, and Alabama) 
and New England (Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and 
Connecticut). The 2014 incidence rates per 1,000 hospital births in these two regions 
were more than twice as high as the national rate of 9.1, with 20.5 (95% CI: 19.2-21.8) 
and 18.6 (95% CI: 17.0-20.1) respectively (Table 4.2 and Figure 4.3).   
4.4.3.  Identification of Personal and Environmental Risk Factors 
Table 4.3 shows the findings from the bivariate and multivariate logistic 
regression analyses. When adjusting for all covariates, the probability of being born with 
a NAS diagnosis was higher among infants who were male, white, born to families with 
lower household incomes, covered by Medicaid, and located in urban, population-dense 
areas. Insurance status (primary payer) had the largest association with the infant being 
diagnosed with NAS.  Being covered by Medicaid, compared to having private insurance, 
increased the odds of neonatal withdrawal more than eight times (OR: 8.55; 95% CI: 
8.41-8.69), and infants without health insurance were nearly 7 times as likely to be 
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diagnosed with NAS (OR: 6.84; 95% CI: 6.65-7.03), when adjusted for the other 
covariates.  
Infants born to families residing in urban areas was a significant risk factor for 
NAS in the adjusted model; however, findings based on the bivariate analysis suggested 
otherwise; i.e., the probability of having a diagnosis of neonatal withdrawal was higher 
in less population-dense areas. A follow-up analysis (cross-tabulation), which was 
conducted to identify the drivers of the discrepancy between the adjusted and 
unadjusted models, indicated that within rural areas there is a large proportion of 
families in the lowest income quartile, covered by Medicaid, and who are white; all of 
which are independent risk factors for NAS. The analysis found that as population 
density decreases, the percentage of patients who are white, poor, and on Medicaid 
increases (see Figure 4.4). 
Among the environmental factors, the previous year’s treatment admission rates 
for opioid misuse in women of childbearing age was associated with the outcome; 
especially living in a region with treatment rates in the fourth quartile (i.e., highest 
treatment rate quartile) compared to the first, increased the odds of having an infant 
born with NAS by 37% (OR: 1.37; 95% CI: 1.31-1.43), when adjusting for the other 
covariates.  
The effect of regional overdose mortality rates was only evident in the bivariate 
analysis, linking rising overdose death rates to greater odds of infants having a NAS 
diagnosis. However, after adjusting for all other covariates, the association became 
insignificant (Table 4.3).  
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4.5.  Discussion 
As previous studies have indicated, the national NAS incidence has been on the 
rise in response to the opioid epidemic 14,15 and the findings from the current study 
show that this trend continues. More often the infants and families affected were white, 
in the lowest income quartile, covered by Medicaid, and living in urban areas, when 
controlling for covariates.  Children diagnosed with neonatal withdrawal required longer 
than average hospital stays, experienced more serious medical conditions, and incurred 
higher hospitalization charges;14,118 all of these outcomes put a significant strain on 
families in terms of costs and suffering. Since Medicaid covered four out of five babies 
born with NAS, most of the healthcare costs fell on the individual states, making the 
issue relevant to state Medicaid budgets. 
An interesting though unexpected result was the association between NAS and 
gender. In the adjusted model, the odds for male infants to be diagnosed with NAS were 
9% higher than for females - a small, yet significant finding. To our knowledge, few 
studies have examined sex differences in NAS risk and findings from those who have 
found inconsistent results. NAS expression and severity have been found to differ 
among affected infants, though the reasons for this variability are still unknown.119 Male 
sex has been linked to a greater vulnerability for developmental deficits throughout 
infancy and childhood120 and male infants have displayed poorer levels of neuro-
behavioral functioning.121 Furthermore, a recent large population-based cohort study 
found that male infants were 18% more likely to suffer from NAS compared to female 
neonates.122  
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The regional variability in NAS incidence rates highlighted areas in the U.S. that 
have been affected the most by the NAS problem, primarily East South Central and New 
England. This points toward a need for targeted policies and additional prevention 
strategies for women of childbearing age specifically in these regions. 
The results of this study found an association between treatment admissions for 
opioid misuse in women ages 15 to 44 and neonatal withdrawal. Given that most 
pregnancies in females who misuse opioids are unintended,117 entering treatment 
provides an opportunity to counsel women of childbearing age on the risks of delivering 
a child with NAS and assist them in their family-planning, including access to 
contraceptives.   
4.5.1.  Strengths and Limitations 
A strength of this study was its large sample size (n=5,538,204 hospital births). 
Data were obtained through HCUP’s NIS, the largest publicly available all-payer inpatient 
health care database in the nation. NIS allows for national and, since 2012, regional 
estimates of health conditions with confidence due to its strong scientific design. 
Furthermore, this study included demographic and environmental (regional) factors in 
the logistic regression analysis to identify additional risk factors of NAS; an approach 
that does not appear to have previously been attempted.  
 Limitations include a growing concern of misclassification bias when using the 
International Classification of Diseases (ICD) codes compared to using clinical scales to 
measure neonatal withdrawal, suggesting a possible undercounting of NAS cases.109 
Though it is possible that some of the increase in NAS incidence may be a result of the 
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attention the syndrome has been receiving in recent years, it is likely that the effect of 
this artifact was minimal, given the sharp increase and consistent incline in NAS cases 
over the past years. 
4.5.2.  Conclusion 
National NAS incidence nearly tripled during the 7-year study period ending in 
2014, continuing a previously observed upward trend across the country. Rates varied 
greatly regionally and were highest in the East South Central and New England regions. 
Healthcare costs associated with a NAS diagnosis can be substantial and the burden falls 
primarily onto individual states since Medicaid is the primary payer for a large portion of 
these cases. To reduce NAS, continued public health efforts are needed at the national 
and state levels to combat the opioid epidemic and implement specific strategies 
targeting women of childbearing age prior to becoming pregnant as well as during 
pregnancy for those misusing opioids. Adequate funding to address this problem, 
particularly in high-risk regions, is crucial.  
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Table 4.1. Characteristics of U.S. hospital births by NAS status, 2008-2014 Table 7 
 NAS Births 
(unweighted n=33,230) 
All Other Births 
(unweighted n=5,504,974) 
 Weighted Weighted  
Mean 95% CI Mean 95% CI 
Length of stay (days) * 13.6 13.4-13.8 3.3 3.3-3.3 
Number of diagnoses * 6.1 6.1-6.2 3.0 3.0-3.0 
Total charges ($) * 50,415 49,268-51,562 11,027 10,976-11,078 
     
 Percentage 95% CI Percentage 95% CI 
Male *  53.4 52.9-54.0 51.2  51.1-51.2 
Race *      
      White 75.5 75.0-76.0 52.3 52.2-52.3 
      Black 8.9 8.6-9.2 13.9 13.9-14.0 
      Hispanic 10.1 9.8-10.5 21.3 21.3-21.3 
      Asian/Pacific Islander 0.6 0.5-0.7 5.3 5.3-5.4 
      Native American 1.5 1.3-1.6 0.8 0.8-0.9 
      Other 3.5 3.3-3.7 6.4 6.4-6.4 
Income quartile *      
      1st quartile (lowest) 36.8 36.3-37.7 27.0 27.0-27.0 
      2nd quartile 27.3 26.8-27.8 25.4 25.3-25.4 
      3rd quartile 22.5 22.1-23.0 24.9 24.9-24.9 
      4th quartile (highest) 13.4 13.0-13.7 22.7 22.7-22.8 
Primary payer *     
     Medicaid 79.2 78.7-79.6 44.6 44.6-44.7 
     Private Insurance 13.0 12.7-13.4 47.8 47.8-47.9 
     Self-Pay 5.5 5.3-5.7 4.5 4.4-4.5 
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 NAS Births 
(unweighted n=33,230) 
All Other Births 
(unweighted n=5,504,974) 
 Weighted Weighted 
     Other 2.3 2.1-2.5 3.1 3.1-3.1 
Patient location     
      Metro county >1 million 49.0 48.5-49.6 57.5 57.4-57.5 
      Metro county >250K but <1 
million 
21.8 21.4-22.3 19.1 19.1-19.1 
      Metro county >50K but <250K 9.4 9.5-10.2 8.9 8.8-8.9 
      Micropolitan 11.5 11.1-11.8 9.1 9.1-9.2 
      Not micro or metro 7.8 7.5-8.1 5.5 5.4-5.5 
* p < .0001 
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Table 4.2. Annual NAS incidence rate* (95% CI) per 1,000 hospital births, by U.S. census 
division 2012-2014 Table 8 
  2012 2013 2014 
New England 13.2 
(11.9-14.5) 
16.8 
(15.3-18.3) 
18.6 
(17.0-20.1) 
Middle Atlantic 6.9 
(6.4-7.5) 
7.9 
(7.4-8.5) 
8.6 
(8.0-9.1) 
East North Central 7.2 
(6.6-7.7) 
8.6 
(8.0-9.1) 
9.8 
(9.2-10.4) 
West North Central 4.4 
(3.8-4.9) 
5.6 
(5.0-6.2) 
5.5 
(4.9-6.2) 
South Atlantic 7.3 
(6.9-7.8) 
8.7 
(8.2-9.2) 
9.4 
(8.9-9.9) 
East South Central 12.9 
(11.8-13.9) 
17.7 
(16.5-19.0) 
20.5 
(19.2-21.8) 
West South Central 3.3 
(2.9-3.6) 
3.9 
(3.5-4.3) 
5.2 
(4.8-5.7) 
Mountain 7.5 
(6.8-8.2) 
9.2 
(8.4-10.0) 
10.0 
(9.2-10.8) 
Pacific 5.4 
(5.0-5.9) 
6.4 
(6.0-6.9) 
6.3 
(5.9-6.8) 
U.S.  6.8  
(6.6-6.9) 
8.2  
(8.0-8.4) 
9.1  
(8.8-9.3) 
*Weighted 
Division 1 (New England): Maine, New Hampshire, Vermont, Massachusetts, Rhode 
Island, Connecticut 
Division 2 (Mid-Atlantic): New York, Pennsylvania, New Jersey 
Division 3 (East North Central): Wisconsin, Michigan, Illinois, Indiana, Ohio 
Division 4 (West North Central): Missouri, North Dakota, South Dakota, Nebraska, 
Kansas, Minnesota, Iowa 
Division 5 (South Atlantic): Delaware, Maryland, District of Columbia, Virginia, West 
Virginia, North Carolina, South Carolina, Georgia, Florida 
Division 6 (East South Central) Kentucky, Tennessee, Mississippi, Alabama 
Division 7 (West South Central) Oklahoma, Texas, Arkansas, Louisiana 
Division 8 (Mountain) Idaho, Montana, Wyoming, Nevada, Utah, Colorado, Arizona, New 
Mexico 
Division 9 (Pacific) Alaska, Washington, Oregon, California, Hawaii 
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Table 4.3. Personal and environmental risk factors linked to NAS (unadjusted and adjusted odds ratios and 95% confidence 
intervals)*  (Table 9 
 Bivariate  (unadjusted) Multivariable (adjusted) 
Effect Odds Ratio 95% CI Odds Ratio 95% CI 
Male infants (ref=female) 1.09 1.08-1.11 1.09 1.08-1.10 
Race of infant (ref=black )     
      White    2.26 2.22-2.31 4.05 3.97-4.13 
      Hispanic 0.74 0.73-0.76 0.79 0.77-0.81 
      Asian/Pacific Islander 0.18 0.17-0.19 0.33 0.31-0.35 
      Native American 2.74 2.62-2.87 3.76 3.57-3.95 
      Other 0.85 0.82-0.88 1.10 1.06-1.13 
Primary payer (ref=private insurance)     
      Medicaid 6.51 6.42-6.61 8.55 8.41-8.69 
      Self-pay 4.52 4.41-4.64 6.84 6.65-7.03 
      Other 2.71 2.62-2.81 2.73 2.62-2.84 
Median household income quartile 
(ref=4 / highest income quartile) 
    
      1st quartile 2.32 2.29-2.36 1.44 1.41-1.46 
      2nd quartile 1.83 1.80-1.86 1.19 1.17-1.21 
      3th quartile 1.54 1.51-1.57 1.13 1.11-1.15 
Patient location (ref=1 / metro areas 
with >1 million pop.) 
    
      Metro areas with 250,000-     
      999,999 pop. 
1.34 1.32-1.36 0.95 0.94-0.97 
      metro areas with 50,000- 
      249,999 pop. 
1.30 1.28-1.33 0.84 0.82-0.86 
      Micropolitan areas 1.48 1.45-1.50 0.75 0.73-0.76 
      Rural (not metro- or micropolitan) 1.68 1.65-1.71 0.74 0.72-0.75 
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 Bivariate  (unadjusted) Multivariable (adjusted) 
Hospital division (ref=9 / East North 
Central) 
    
      New England 2.33 2.20-2.29 2.60 2.54-2.68 
      Middle Atlantic 1.03 1.01-1.05 1.33 1.29-1.36 
      West North Central 0.63 0.62-0.65 0.91 0.87-0.95 
      South Atlantic 1.11 1.09-1.12 1.57 1.50-1.63 
      East South Central 2.24 2.20-2.29 1.55 1.51-1.59 
      West South Central 0.54 0.53-0.55 0.70 0.67-0.72 
      Mountain 1.09 1.07-1.12 1.47 1.41-1.53 
      Pacific 0.81 0.79-0.82 1.69 1.61-1.77 
Opioid treatment rate 1-year lag (ref=1 / 
lowest rate quartile) 
    
      2nd quartile 0.73 0.72-0.74 0.96 0.94-0.98 
      3rd quartile 0.78 0.76-0.79 1.18 1.14-1.23 
      4th quartile 1.51 1.50-1.53 1.37 1.31-1.43 
Overdose mortality rate 1.14 1.14-1.15 1.01 1.00-1.01 
Year 1.18 1.17-1.18 1.14 1.13-1.14 
 *Weighted 
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Figure 4.1. Average NAS incidence rate* per 1,000 hospital births by population density 
of patient location, 2008-2014 Figure 5 
 
*Weighted as per the National Inpatient Sample instructions 
 
 
Figure 4.2. Annual NAS incidence rate* per 1,000 hospital births, United States 2008-
2014 Figure 6(Figu 
 
*Weighted as per the National Inpatient Sample instructions 
5.1
6.9 6.7
7.5
8.6
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
Metro > 1
million
Metro
between 250K
and 1 million
Metro
between 50K
and 250K
Micro < Micro
3.1
4.3
5.7 5.8
6.8
8.2
9.1
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
2008 2009 2010 2011 2012 2013 2014
  
61 
 
 
Figure 4.3. Annual NAS incidence rate* per 1,000 hospital births, by U.S. census division 
2012-2014 (Figure 7) 
 
* Weighted  
 
Division 1 (New England): Maine, New Hampshire, Vermont, Massachusetts, Rhode 
Island, Connecticut 
Division 2 (Mid-Atlantic): New York, Pennsylvania, New Jersey 
Division 3 (East North Central): Wisconsin, Michigan, Illinois, Indiana, Ohio 
Division 4 (West North Central): Missouri, North Dakota, South Dakota, Nebraska, 
Kansas, Minnesota, Iowa 
Division 5 (South Atlantic): Delaware, Maryland, District of Columbia, Virginia, West 
Virginia, North Carolina, South Carolina, Georgia, Florida 
Division 6 (East South Central) Kentucky, Tennessee, Mississippi, Alabama 
Division 7 (West South Central) Oklahoma, Texas, Arkansas, Louisiana 
Division 8 (Mountain) Idaho, Montana, Wyoming, Nevada, Utah, Colorado, Arizona, New 
Mexico 
Division 9 (Pacific) Alaska, Washington, Oregon, California, Hawaii 
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Figure 4.4. Percentage of patients in the lowest income quartile, covered by Medicaid, 
and who are white by patient location* Figure 8 
 
*Weighted 
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Micropolit
an
< Micro
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Lowest income 20.5% 28.9% 32.4% 43.2% 56.5%
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CHAPTER 5 Conclusion  
In the United States, the misuse of opioids, prescribed or illicit, has risen 
significantly over the past two decades. This has led to increases in treatment 
admissions for opioid misuse and addiction (Chapter 2); drug overdoses, many of which 
resulted in death; and infants born with neonatal abstinence syndrome (Chapter 4). 
Furthermore, persons addicted to opioids, especially heroin, frequently inject these 
drugs (Chapter 2). Sharing injection paraphernalia puts users at risk for getting or 
transmitting infectious diseases such as HIV and Hepatitis C.123,124 It is estimated that 
approximately 10 percent of new HIV cases are linked to IDU.125 
The liberal prescribing of opioids by healthcare professionals in the 1990s and 
2000s is believed to have contributed significantly to the epidemic4 by increasing the 
availability of prescription opioids in communities22 and by raising the risk of addiction 
in patients who receive long-term opioid therapy.126 However, prescribing practices are 
changing again and the Centers for Disease Control and Prevention have released opioid 
prescribing guidelines in 2016 to reduce overprescribing.31  
5.1.  Public Health Recommendations 
The overall costs of the opioid epidemic in terms of financial expenditures and 
human suffering are extremely high.14,40,52,127 Public health responses at the federal, 
state, and local levels have been substantial, but these efforts need to be maintained 
and expanded to successfully curb the problem. Based on findings from these studies 
(Chapters 2 through 4), the following strategies are recommended: 
CHAPTER 2 
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The percentage of substance use treatment admissions attributable to opioids 
has increased significantly over the past years, indicating an expanding need for 
effective programs to treat opioid use disorder. Though not everyone who misuses 
prescription opioids progresses to heroin, for many in Indiana’s treatment population 
this was the case. Over two-thirds of heroin users in treatment inject the drugs 
intravenously, which puts them at a high risk for transmitting infectious diseases such as 
HIV and hepatitis B and C. 
1. Provide access to evidence-based treatment services for opioid use disorder 
(e.g., medication-assisted treatment). 
2. Implement programs to reduce transmission of HIV and hepatitis B and C (e.g., 
syringe exchange programs). 
CHAPTER 3 
Receiving two or more monthly opioids, on average, and two or more 
benzodiazepines per year was highly associated with opioid-related risk activities in 
patients. Healthcare providers who routinely check patients’ prescription drug history 
prior to prescribing a controlled substance may be in a better position to identify those 
at risk for opioid-related problem behaviors. To help reduce the burden on the 
healthcare system, integrating PDMP data with electronic health records (EHRs) would 
save physicians time and effort when accessing patients’ charts. Some patients are 
willing to cross state lines in their pursuit of opioid prescriptions. Data-sharing 
agreements among PDMPs from multiple states and potentially a national PDMP system 
would allow for more complete monitoring of problematic behaviors in patients or 
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prescribers.  
3. Encourage healthcare providers to conduct routine PDMP checks prior to 
prescribing a controlled substance.  
4. Integrate PDMP data with EHRs to ease the burden on the healthcare system.  
5. Establish PDMP data-sharing protocols across state lines and consider a national 
PDMP system. 
CHAPTER 4 
Incidence rates of neonatal abstinence syndrome (NAS) continue to rise across 
the country; varying greatly among U.S. regions. Healthcare costs associated with the 
diagnosis can be substantial and fall primarily to individual states by means of Medicaid 
as the primary payer to a large portion of these cases.  Women of childbearing age who 
are addicted to opioids are the target population for prevention and intervention. 
Implementing specific strategies prior to these women becoming pregnant as well as 
during pregnancy is crucial.  
6. Counsel women of childbearing age who misuse opioids on the risks of NAS and 
assist them in family-planning, including access to contraceptives.  
7. Provide access to treatment for pregnant women addicted to opioids. 
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